Tomer Kariv sold $85M of KROS
director, owner at Keros Therapeutics, Inc.. 4,787,331 shares at an average of $17.75, traded Oct 15, 2025, filed Oct 17, 2025.
Score components
- +15RoleDirector
- +25Trade size$85.0M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- +10Role exitThe filing reports the insider leaving
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +24.8%, 3m +36.4%, 6m -15.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000921895-25-002765, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax (Israel) IV, L.P. | -2,284,612 | $17.75 | $41M | 0 | Oct 17, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax (Cayman) IV, L.P. | -1,121,045 | $17.75 | $20M | 0 | Oct 17, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax (China) IV, L.P. | -1,226,412 | $17.75 | $22M | 0 | Oct 17, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax Late Stage Fund, L.P. | -155,262 | $17.75 | $2.8M | 0 | Oct 17, 2025 |
Related signals
Other insiders at Keros Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Keros Therapeutics, Inc. | Esther Cho Chief Legal Officer | $46k 4,485 shares | -11% | |
| 10Weak | Keros Therapeutics, Inc. | Charles W. Newton director | $5,675 551 shares | -4% | |
| 41Moderate | Keros Therapeutics, Inc. | Lorena Raquel Lerner Chief Scientific Officer | $37k 3,568 shares | -11% | |
| 30Weak | Keros Therapeutics, Inc. | Annita Tanini Corp. Controller & VP, Finance | $13k 1,224 shares | -3% | |
| 36Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $10k 1,000 shares | +5% | |
| 26Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $11k 1,000 shares | +6% | |
| 26Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $10k 1,000 shares | +6% | |
| 10Weak | Keros Therapeutics, Inc. | Charles W. Newton director | $5,522 550 shares | -4% | |
| 20Weak | Keros Therapeutics, Inc. | Nima Farzan director | $28k 2,625 shares | -21% | |
| 20Weak | Keros Therapeutics, Inc. | Julius Knowles director | $28k 2,625 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.